Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
Introduction Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction of them obtain a response, and clinical benefit from these treatments is often difficult to predict. The aim of our study is to unveil the pote...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/11/e009931.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846122255724052480 |
|---|---|
| author | Francois-Xavier Danlos Aurélien Marabelle Tyler Hulett Fabrice Barlesi Benjamin Besse David Planchard Nathalie Chaput-Gras Mihaela Aldea Filippo G Dall’Olio Paul-Henry Cournède Quentin Blampey Wael Salem Zrafi Matthieu Roulleaux-Dugage Gabriel Roman Charles Naltet Daniel Gautheret |
| author_facet | Francois-Xavier Danlos Aurélien Marabelle Tyler Hulett Fabrice Barlesi Benjamin Besse David Planchard Nathalie Chaput-Gras Mihaela Aldea Filippo G Dall’Olio Paul-Henry Cournède Quentin Blampey Wael Salem Zrafi Matthieu Roulleaux-Dugage Gabriel Roman Charles Naltet Daniel Gautheret |
| author_sort | Francois-Xavier Danlos |
| collection | DOAJ |
| description | Introduction Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction of them obtain a response, and clinical benefit from these treatments is often difficult to predict. The aim of our study is to unveil the potential implications of antibody response to previous viral infections in predicting response to ICBs in patients with NSCLC.Methods Sera from patients treated with ICBs alone, chemotherapy (CT) or a combination of CT-ICBs were analyzed with VirScan (CDI Labs, USA), a high-throughput method that comprehensively analyzes epitope-level antiviral IgG antibodies via programmable phage display and immunoprecipitation sequencing.Total number of unique positive peptides (tUP) was defined as the total number of non-overlapping positive “is a hit” peptides for each patient.Results Overall, 387 patients were included. Of them, 129 were treated with ICBs alone, 66 with CT-ICBs and 195 with CT alone. 90 out of 129 patients treated with ICBs alone received ICBs as a subsequent line of treatment, while CT-ICBs and CT were administered as upfront therapies.A higher tUP was correlated with improved overall survival in patients treated with ICBs, and confirmed in the multivariate model (HR 0.43, 95% CI 0.24, 0.79, p=0.006), while it was not in those treated with CT-ICBs (p=0.8) and CT alone (p=0.1).tUP was not correlated with programmed death-ligand 1 (PD-L1) expression, while at the transcriptome level it was correlated with several immune-related pathways, particularly involving B cells.Conclusion A higher number of viral peptides recognized by serum antibodies might reflect increased immune fitness, resulting in improved outcomes in ICBs treated patients with NSCLC. |
| format | Article |
| id | doaj-art-7a4afe6d68924f048a0dce12c5e75fb6 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-7a4afe6d68924f048a0dce12c5e75fb62024-12-14T22:05:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-11-01121110.1136/jitc-2024-009931Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancerFrancois-Xavier Danlos0Aurélien Marabelle1Tyler Hulett2Fabrice Barlesi3Benjamin Besse4David Planchard5Nathalie Chaput-Gras6Mihaela Aldea7Filippo G Dall’Olio8Paul-Henry Cournède9Quentin Blampey10Wael Salem Zrafi11Matthieu Roulleaux-Dugage12Gabriel Roman13Charles Naltet14Daniel Gautheret15Universite Paris-Saclay, Gif-sur-Yvette, FranceDrug Development Department (DITEP), Gustave Roussy, Villejuif, FranceCDI Laboratories Inc, Baltimore, Maryland, USAUniversite Paris-Saclay, Gif-sur-Yvette, FranceUniversite Paris-Saclay, Gif-sur-Yvette, FranceUniversite Paris-Saclay, Gif-sur-Yvette, FranceLaboratoire d`immunomonitoring En Oncologie, University Paris-Saclay, Faculty of Pharmacy, Gustave Roussy Cancer Campus, Villejuif, FranceUniversite Paris-Saclay, Gif-sur-Yvette, FranceDepartment of Head and Neck Oncology, Gustave Roussy, Villejuif, FranceUniversite Paris-Saclay, Gif-sur-Yvette, FranceCentraleSupelec, Gif-sur-Yvette, FranceDepartment of Biostatistics and Bioinformatics, Gustave Roussy, Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, Villejuif, FranceCDI Laboratories Inc, Baltimore, Maryland, USADepartment of Respiratory Diseases, Hôpital Paris Saint-Joseph, Paris, FranceUniversite Paris-Saclay, Gif-sur-Yvette, FranceIntroduction Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction of them obtain a response, and clinical benefit from these treatments is often difficult to predict. The aim of our study is to unveil the potential implications of antibody response to previous viral infections in predicting response to ICBs in patients with NSCLC.Methods Sera from patients treated with ICBs alone, chemotherapy (CT) or a combination of CT-ICBs were analyzed with VirScan (CDI Labs, USA), a high-throughput method that comprehensively analyzes epitope-level antiviral IgG antibodies via programmable phage display and immunoprecipitation sequencing.Total number of unique positive peptides (tUP) was defined as the total number of non-overlapping positive “is a hit” peptides for each patient.Results Overall, 387 patients were included. Of them, 129 were treated with ICBs alone, 66 with CT-ICBs and 195 with CT alone. 90 out of 129 patients treated with ICBs alone received ICBs as a subsequent line of treatment, while CT-ICBs and CT were administered as upfront therapies.A higher tUP was correlated with improved overall survival in patients treated with ICBs, and confirmed in the multivariate model (HR 0.43, 95% CI 0.24, 0.79, p=0.006), while it was not in those treated with CT-ICBs (p=0.8) and CT alone (p=0.1).tUP was not correlated with programmed death-ligand 1 (PD-L1) expression, while at the transcriptome level it was correlated with several immune-related pathways, particularly involving B cells.Conclusion A higher number of viral peptides recognized by serum antibodies might reflect increased immune fitness, resulting in improved outcomes in ICBs treated patients with NSCLC.https://jitc.bmj.com/content/12/11/e009931.full |
| spellingShingle | Francois-Xavier Danlos Aurélien Marabelle Tyler Hulett Fabrice Barlesi Benjamin Besse David Planchard Nathalie Chaput-Gras Mihaela Aldea Filippo G Dall’Olio Paul-Henry Cournède Quentin Blampey Wael Salem Zrafi Matthieu Roulleaux-Dugage Gabriel Roman Charles Naltet Daniel Gautheret Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer Journal for ImmunoTherapy of Cancer |
| title | Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer |
| title_full | Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer |
| title_fullStr | Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer |
| title_full_unstemmed | Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer |
| title_short | Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer |
| title_sort | antecedent viral immunization and efficacy of immune checkpoint blockade an extensive serum antibody profile to predict outcomes in non small cell lung cancer |
| url | https://jitc.bmj.com/content/12/11/e009931.full |
| work_keys_str_mv | AT francoisxavierdanlos antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT aurelienmarabelle antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT tylerhulett antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT fabricebarlesi antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT benjaminbesse antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT davidplanchard antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT nathaliechaputgras antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT mihaelaaldea antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT filippogdallolio antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT paulhenrycournede antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT quentinblampey antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT waelsalemzrafi antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT matthieuroulleauxdugage antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT gabrielroman antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT charlesnaltet antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer AT danielgautheret antecedentviralimmunizationandefficacyofimmunecheckpointblockadeanextensiveserumantibodyprofiletopredictoutcomesinnonsmallcelllungcancer |